Headquartered in Melville, NY, Henry Schein, Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 32 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its first quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at 92 cents per share. Henry Schein’s adjusted earnings per share of 95 cents exceeded the estimate by 3.2%.
Revenues: Henry Schein posted net sales of $3.22 billion, ahead of the Zacks Consensus Estimate for revenues of $3.17 billion.
Key Stats: Revenues in the first quarter derived from Henry Schein’s Dental segment grew 10.2% year over year to $1.5 billion, while Animal Health segment recorded sales of $919.8 million, up 13.1% compared with the prior-year quarter. Revenues from Medical segment increased 6.9% year over year to $640.4 million, while sales from Technology and Value-added services segment grew 6.1% to $112.4 million.
Major Factors: Henry Schein’s four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company has reiterated its earlier-provided 2018 EPS guidance range of $4.03 to $4.14.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Headquartered in Melville, NY, Henry Schein, Inc. (HSIC - Free Report) is a global leading provider of healthcare products and services. The company serves office-based dental, medical and animal health practitioners, dental laboratories, government as well as institutional health care clinics and other alternate-care sites. Presently, Henry Schein serves more than 1 million customers and has operations in 32 countries. The company entered the prestigious Standard & Poor's (S&P) 500 Index in Mar, 2015.
Currently, Henry Schein has a Zacks Rank #2 (Buy) but that could change following its first quarter 2018 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate is pegged at 92 cents per share. Henry Schein’s adjusted earnings per share of 95 cents exceeded the estimate by 3.2%.
Revenues: Henry Schein posted net sales of $3.22 billion, ahead of the Zacks Consensus Estimate for revenues of $3.17 billion.
Key Stats: Revenues in the first quarter derived from Henry Schein’s Dental segment grew 10.2% year over year to $1.5 billion, while Animal Health segment recorded sales of $919.8 million, up 13.1% compared with the prior-year quarter. Revenues from Medical segment increased 6.9% year over year to $640.4 million, while sales from Technology and Value-added services segment grew 6.1% to $112.4 million.
Major Factors: Henry Schein’s four global segments gained solid market share during the quarter and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions. The company has reiterated its earlier-provided 2018 EPS guidance range of $4.03 to $4.14.
Stock Price: Following the earnings release, share prices did not show any significant movement in the pre-market trading session.
Check back later for our full write up on this Henry Schein earnings report later!
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on HSIC - FREE